19.7 0.7 (3.68%) | 02-18 15:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 25.69 | 1-year : | 30.01 |
Resists | First : | 22 | Second : | 25.69 |
Pivot price | 19.97 ![]() |
|||
Supports | First : | 18.29 | Second : | 16 |
MAs | MA(5) : | 20.46 ![]() |
MA(20) : | 19.43 ![]() |
MA(100) : | 19.58 ![]() |
MA(250) : | 13.06 ![]() |
|
MACD | MACD : | 0.2 ![]() |
Signal : | 0.1 ![]() |
%K %D | K(14,3) : | 73.1 ![]() |
D(3) : | 77.2 ![]() |
RSI | RSI(14): 49.7 ![]() |
|||
52-week | High : | 22.14 | Low : | 3.13 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ZIVO ] has closed above bottom band by 40.9%. Bollinger Bands are 34.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 21.27 - 21.37 | 21.37 - 21.46 |
Low: | 19.5 - 19.61 | 19.61 - 19.72 |
Close: | 20.77 - 20.95 | 20.95 - 21.12 |
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.
Thu, 06 Feb 2025
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry - Marketscreener.com
Thu, 06 Feb 2025
Revolutionary Algae-Based Solution Shows Promise in Fighting Bird Flu: ZIVO's Latest Research Breakthrough - StockTitan
Tue, 28 Jan 2025
Zivo Bioscience issues new shares, raises $1.5 million - MSN
Wed, 22 Jan 2025
ZIVO Bioscience to Present at The Microcap Conference 2025: Showcasing Algal Biotech Innovations - StockTitan
Fri, 23 Aug 2024
Director and 10% Owner Christopher Maggiore Acquires 31,336 Shares of Zivo Bioscience Inc (ZIVO) - Yahoo Finance
Tue, 22 Aug 2023
Algal ingredient specialist ZIVO makes partnership for production and distribution - Nutraceutical Business Review
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 0 (M) |
Held by Insiders | 3.37e+006 (%) |
Held by Institutions | 1.77e+006 (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -5.33 |
Profit Margin | 0 % |
Operating Margin | -21 % |
Return on Assets (ttm) | 871.9 % |
Return on Equity (ttm) | -1 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | -3.7 |
Price to Sales | 0 |
Price to Cash Flow | 0 |
Dividend | 35470 |
Forward Dividend | 12810 |
Dividend Yield | 180051% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |